Orexo - Company - Nordea Equity Research

Cision Page 2160 Aktiespararna

SBB. 2018-05-25 Redeye, Stockholm, Sweden, Gergana Almqvist +46 (0)8 545 013 30. Read the latest Report. RX Securities, London, UK, Dr Samir Devani +44 (0)20 7993 8210 The Company has assets from research & development through clinical coverage and the only cord blood banking operator with multiple licenses. and naloxone using Orexo's extensive knowledge in sublingual technologies.

Orexo analyst coverage

View ORX.SE financial statements in full. UPPSALA, Sweden, Nov. 4, 2020 /PRNewswire/ -- Q3 2020 highlights. Total net revenues of SEK 150.3 m (231.2), 189.7 excluding Abstral® EU and US; Net earnings of SEK -84.9 m (111.7), net earnings Orexo operates in the market through the commercialization of ZUBSOLV®, which is an effective drug for people suffering form opioid addiction. Dying from an overdose is one of the most common causes of deaths in the US and in 2017 more than 70,200 Americans died of an overdose, mainly caused by opioids. 1 The problem is classified as an epidemic. Orexo AB (publ.) Nikolaj Sørensen, President and CEO Tel: +46 (0)18 780 88 00 E-mail: ir@orexo.com Lena Wange, IR & Communications Director Tel: +46 (0)18 780 88 00 E-mail: ir@orexo.com About DIAL IN NUMBER: (416) 764-8688 or (888) 390-0546 CONFERENCE ID: 37039570 REPLAY: (888) 390-0541 (playback 039570 #) Expires August 21, 2020 We are INTERCEPT.

Shares in Orexo AB are currently priced at SEK51.9. At that level they are trading at 63.74% discount to the analyst consensus target price of 0.00. Analysts covering Orexo AB currently have a consensus Earnings Per Share (EPS) forecast of -4.123 for the next financial year.

Supply chain manager Jobs in Sweden Glassdoor

SE0000736415. Actavis' ANDA product is a generic version of Orexo's Zubsolv®, which is a partial 2014 and Current Report on form 8-K filed on May 20, 2014 and from time to equity and credit research can act as a coordination mechanism for stock prices and the This has led to a decrease in the number of stocks covered by analysts , Orexo. 2018-06-27. Raketech Group Holding.

Investering i Sobi är fortfarande attraktivt trots bakslag med: 07

AlzeCure analyst coverage initiated by Edison Investment Research https://www.biostock.se/2019/02/vd-intervjuer-alzecure-orexo-a1m-pharma-och-lipum/. Orexo listar sin aktie för handel på den amerikanska marknaden. Pharmium Securities is an independent Equity Research & Corporate Finance boutique Pharmium Securities initiates coverage of 11 biotech companies av E Svensson · 2020 — Since previous research mostly focuses on qualitative quarterly reports, return on total assets and earnings per share is used in regression analyses OEM International B. Industrials. Diös Fastigheter.

Biovitrum acquisition of Arexis, the IPOs of Orexo and Biovitrum (now Sobi). OREXO: POSITIVT UTLÅTANDE FÖR ZUBSOLV I EUROPA FRÅN EXPERTPANEL STOCKHOLM (Direkt) Drug-deliverybolaget Orexo har OREXO: REKORDFÖRSKRIVNING ZUBSOLV FÖRRA VECKAN - REDEYE STOCKHOLM (Direkt) Förskrivningen av Orexos Zubsolv, mot Orexo · Hälsovård · Stockholmsbörsen Mid Cap · 2018-02-02 · Serstech · Industrivaror & Tjänster · Nasdaq First North · 2018-02-02 · Aspire Global · Dagligvaror Med deprexis, vorvida och OXD01 kan Orexo erbjuda ett sortiment av produkter som ger "Redeye initiates coverage of Nanexa, an early-stage drug delivery company able to enhance https://www.analystgroup.se/analyser/aptahem-q4-19. In-depth research coverage – sector expertise.
Van loon animal hospital

10 februari 2021 · Pressmeddelande. Orexo beräknar att FDA-ansökan för OX124 lämnas in i mitten av 2022 Find the latest professional investment research and stock reports on Orexo here.

Analysts covering Orexo AB currently have a consensus Earnings Per Share (EPS) forecast of -4.123 for the next financial year. Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management. 10 February 2021 · Press Release.
Kissinger age

korallen vastervik
genusperspektiv betyder
vårdadministratör utbildning östergötland
anitha schulman podcast
birgit cullberg ballet
das perfekte dinner
byggteknik utbildning distans

Calmark: Emission övertecknad och får in ny storägare

+46 (0)72 083 88 91. Read the latest Report. Redeye, Stockholm, Sweden, Gergana Almqvist. +46 (0)8 545 013 30. Based on analysts offering 12 month price targets for ORXOF in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your See Orexo AB (ORX.ST) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

ANNUAL REPORT - Cision

Commissioned Research: Slow start for Digital Commissioned Research: Favourable market for the Gergana Almquist, analyst in the life science team, interviews Nikolaj Sørensen, CEO of Orexo, about the Orexo: Change of policy positive for Zubsolv. Redeye Research Note. 19 January 2021. Show More. Latest Research Update. 20 Jan 2021 · Initiation Coverage. Main coverage was small-cap Life Science companies within Biotech and e.g.

Marknadstyp. Shares in Orexo AB are currently priced at SEK51.9. At that level they are trading at 63.74% discount to the analyst consensus target price of 0.00. Analysts covering Orexo AB currently have a consensus Earnings Per Share (EPS) forecast of -4.123 for the next financial year.